01—Abstract
Summary
Summary of the 10-Q filed March 8, 2016. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported a net revenue of $1.028 billiona for the three months ended January 31, 2016, which was flat compared to the prior year period.
Despite a 2% revenue decline in Products, Services and other revenue increased by 7% to $233 millionb. The company saw mixed segment performance, with Life Sciences and Applied Markets revenue down 4% and Diagnostics and Genomics up 7%, while Agilent CrossLab grew 4%. Net income from continuing operations significantly increased by 32% to $123 million, translating to diluted EPS of $0.37, up from $0.19 in the prior year.
This improvement was driven by higher gross and operating margins, aided by cost controls and a pension curtailment gain, along with reduced R&D expenses. Financially, Agilent maintained a strong liquidity position with $1.931 billionc in cash and cash equivalents. The company generated $104 million in cash from operations, a substantial improvement from the $20 million used in the prior year.
Agilent continued its capital return strategy by repurchasing $200 milliond of its stock and paying $38 million in dividends during the quarter. The acquisition of Seahorse Bioscience for $242 million was completed, adding to the company's strategic investments and goodwill.
02—Key points
Key Highlights
- Net revenue remained stable at $1.028 billion, with a 7% increase in Services and other revenue offsetting a 2% decrease in Products revenue.
- Net income from continuing operations surged by 32% to $123 million, resulting in diluted EPS of $0.37, a significant improvement from $0.19 in the prior year.
- Operating margin improved by 400 basis points to 15.1%, driven by higher gross margins and cost management initiatives, including a pension curtailment gain.
- Cash flow from operations turned positive, generating $104 million, a substantial turnaround from the $20 million used in the prior year period.
- The company actively returned capital to shareholders, repurchasing $200 million in stock and paying $38 million in dividends.
- Agilent completed the acquisition of Seahorse Bioscience for $242 million, adding to goodwill and strategic investments.
- A material weakness in internal controls related to income tax accounting was identified and is being addressed, though it continues to exist.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2016, Agilent Technologies, Inc. kept $0.12.
- Revenue$1.03B100.0%
- Cost of revenue−$491.0M47.8%
- Gross profit$537.0M52.2%
- Operating costs−$382.0M37.2%
- Operating income$155.0M15.1%
- Interest, other & tax−$32.0M3.1%
- Net income$123.0M12.0%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2016filed March 8, 2016Financial Statements
Q1 FY2016 against Q1 FY2015
| Line item | Q1 FY2016Q1 FY2015 | Change |
|---|---|---|
| Revenue | $1.03B$1.03B | +0.2% |
| Cost of Revenue | $491.00M$513.00M | −4.3% |
| Gross Profit | $537.00M$513.00M | +4.7% |
| R&D Expenses | $78.00M$88.00M | −11.4% |
| SG&A Expenses | $304.00M$310.00M | −1.9% |
| Operating Expenses | $873.00M$911.00M | −4.2% |
| Operating Income | $155.00M$115.00M | +34.8% |
| Interest Expense | $18.00M$16.00M | +12.5% |
| Net Income | $123.00M$63.00M | +95.2% |
| EPS (Basic) | $0.37$0.19 | +94.7% |
| EPS (Diluted) | $0.36$0.19 | +89.5% |
| Shares Outstanding (Basic) | 329.00M336.00M | −2.1% |
| Shares Outstanding (Diluted) | 332.00M338.00M | −1.8% |
05—Questions
Frequently Asked Questions
What is the overall revenue performance for Agilent in this quarter?
Agilent Technologies reported flat net revenue of $1.028 billion for the three months ended January 31, 2016, compared to the same period last year. While Product revenue saw a slight decrease, Services and other revenue experienced a notable increase of 7%.
How did the company's profitability change?
Profitability saw a significant improvement. Net income from continuing operations increased by 32% to $123 million, leading to diluted earnings per share of $0.37, up from $0.19 in the prior year. This was driven by a 400 basis point improvement in operating margin to 15.1%, benefiting from higher gross margins and cost control measures.
What is the company's cash flow situation and how is it returning capital to shareholders?
Agilent generated a strong $104 million in cash from operating activities, a significant improvement from the prior year. The company also actively returned capital to shareholders through $200 million in stock repurchases and $38 million in dividend payments during the quarter.
Are there any significant acquisitions or strategic moves mentioned?
Yes, Agilent completed the acquisition of Seahorse Bioscience for $242 million during the quarter. This acquisition was integrated into the company's financial statements and contributed to goodwill.
06—Continue